ESMO 2024 – Incyte tries again in anal cancer
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
It’s back to school for biotech, with a packed conference schedule.
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.